Stocks · Health care · Pharmaceutical Preparations

Entrada Therapeutics, Inc.

TRDA Clue Score28
United States Fiscal year ends December CIK 0001689375 Results filed 5 Nov 2026

What the insiders did No buying or selling

By person

10 insiders · 0 transactions
5.8×

Dipal Doshi holds 5.8 times base salary in stock. $3.69M of shares against $635.00K in salary for 2025.

Salary from the company's own proxy. The shares are what Dipal Doshi last reported holding, valued at $7.13, the price Common Stock was last bought or sold at on the open market here, on 9 Sep 2026.

Insider
Role
Bought
Sold
Net
Holding
Worth
Change
Mpm Bioventures 2018, L.p.
10% owner
—
—
—
8,203,463
$58.49M
−6.2%
MPM BioVentures 2014, L.P.
10% owner
—
—
—
8,203,463
$58.49M
−6.2%
Baker Bros. Advisors LP entity
10% owner
—
—
—
4,691,392
$33.45M
+4.6%
5AM Ventures V, L.P. entity
10% owner
—
—
—
3,877,094
$27.64M
−12.1%
Kush Parmar
Director
—
—
—
2,691,337
$19.19M
−18.8%
Dipal Doshi
CEO
—
—
—
517,290
$3.69M
+58.8%
Natarajan Sethuraman
President, Research & Develop.
—
—
—
214,238
$1.53M
+29.8%
Nathan J Dowden
President & COO
—
—
—
196,060
$1.40M
+56.7%
Kory James Wentworth
Chief Financial Officer
—
—
—
117,277
$836.19K
+53.3%
Bernhardt G Zeiher
Director
—
—
—
5,000
$35.65K
—

No percentages here. These insiders hold more than one class of share between them, and the share count on file covers one of them rather than all. Dividing the two would compare different things.